The Neurological Safety of Epidural Pamidronate in Rats by Lee, Pyung Bok et al.
Received March 5, 2010. Revised March 19, 2010. Accepted March 30, 2010.
Correspondence to: Sang Hyun Park, MD
Department of Anesthesiology and Pain Medicine, Jeju National University Hospital, College of Medicine, 1753-3, Ara 1-dong, Jeju 690-756, Korea.
Tel:  ＋82-64-717-2026, Fax: ＋82-64-717-2042, E-mail: ppsshh11@daum.net
 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:// 
creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Copyright  ⓒ The Korean Pain Society, 2010
Korean J Pain 2010 June; Vol. 23, No. 2: 116-123
pISSN 2005-9159 eISSN 2093-0569
DOI：10.3344/kjp.2010.23.2.116
| Original Article |
The  Neurological  Safety  of  Epidural  Pamidronate  in  Rats
D e p a r t m e n t  o f  A n e s t h e s i o l o g y  a n d  P a i n  M e d i c i n e ,  J e j u  N a t i o n a l  U n i v e r s i t y  C o l l e g e  o f  M e d i c i n e ,  J e j u ,
*Seoul National University College of Medicine, Seoul, 
†Samsung Seoul Hospital, 
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 
Pyung  Bok  Lee,  MD*,  Yong  Chul  Kim,  MD*,  Chul  Joong  Lee,  MD
†, 
Hye  Young  Shin,  MD,  Seung  Yun  Lee,  MD,  Jong  Cook  Park,  MD, 
Yun  Suk  Choi,  MD,  Chong  Soo  Kim,  MD*,  and  Sang  Hyun  Park,  MD
Background: 
Pamidronate is a potent inhibitor of osteoclast-mediated bone resorption. Recently, the drug has been known 
to relieve bone pain. We hypothesized that direct epidural administration of pamidronate could have various 
advantages over oral administration with respect to dosage, side effects, and efficacy. Therefore, we evaluated 
the neuronal safety of epidurally-administered pamidronate. 
Methods: 
Twenty-seven rats weighing 250-350 g were equally divided into 3 groups. Each group received an epidural 
administration with either 0.3 ml (3.75 mg) of pamidronate (group P), 0.3 ml of 40% alcohol (group A), or 
0.3 ml of normal saline (group N). A Pinch-toe test, motor function evaluation, and histopathologic examination 
of the spinal cord to detect conditions such as chromatolysis, meningeal inflammation, and neuritis, were 
performed on the 2nd, 7th, and 21st day following administration of each drug. 
Results: 
All rats in group A showed an abnormal response to the pinch-toe test and decreased motor function during 
the entire evaluation period. Abnormal histopathologic findings, including neuritis and meningeal inflammation 
were observed only in group A rats. Rats in group P , with the exception of 1, and group N showed no significant 
sensory/motor dysfunction over a 3-week observation period. No histopathologic changes were observed in 
groups P and N. 
Conclusions: 
Direct epidural injection of pamidronate (about 12.5 mg/kg) showed no neurotoxic evidence in terms of 
sensory/motor function evaluation and histopathologic examination. (Korean  J  Pain  2010;  23:  116-123)
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INTRODUCTION
    Bisphosphonates are pyrophosphate derivatives that 
bind to the inorganic matrix of bone, and thereby strongly 
inhibit bone resorption [1,2]. This class of drugs was pre-
viously considered for treatment of osteoporosis for con-
ditions in which hormone replacement therapy is restricted. 
In recent years, however, it has been reported that bi-
sphosphonates have analgesic properties for non-bone- 
related pains in v arious preclinical animal models [3-8]. 
Bonabello et al. [3] showed both a peripherally and cen-
trally  mediated  analgesic  action  of  4  bisphosphonates. 
They used intravenous and intracerebroventricular injection 
for  observing  the  peripheral  and  central  effect  of  bi-
sphosphonates and both showed a dose-dependent anti-
nociception.  In  addition,  some  biological  effects  of  bi-
sphosphonates are mediated through CNS dendritic cells 
and microglia [9]. Based on these, the epidural admin-
istration of bisphosphonates can be an alternative for the 
treatment  of  non-bone-related  pain.  Currently,  bi-
sphosphonates are used clinically by oral administration or 
i n t r a v e n o u s  i n j e c t i o n .  T h e  m a j o r  d i s a d v a n t a g e  o f  o r a l l y 
administrated bisphosphonates is their poor absorption in 
the gastrointestinal tract [9]. Thus, a relatively high dose 
of bisphosphonates must be given by intravenous infusion 
for a rapid and considerable effect. However, intravenous 
administration  causes  gastrointestinal  disturbances,  in-
cluding nausea, vomiting, and diarrhea, as well as sus-
ceptibility to electrolyte imbalance, renal dysfunction, ane-
mia, and hypertension. Moreover, This class of drugs is 
expensive, and requires hospitalization for long-term in-
travenous injection [1,2]. Neuroaxial block, such as epidural 
administration of the drug is expected to reduce dosage, 
as compared with an oral or intravenous infusion, thereby 
minimizing systemic adverse effects and maximizing treat-
ment efficacy [10]. This type of administration method has 
been  of  great  interest  in  the  field  of  pain  medicine. 
Because it is a non-invasive method, it can be admini-
stered long-term and the risk of neurotoxicity is lower. 
    Although the drug is used saf ely f or systemic admin-
istration, it has been well established that animal experi-
ments must be performed to assess efficacy and safety 
when the drug is administered to the subarachnoid or epi-
dural space [10]. Especially, when the safety is confirmed, 
we can conduct the preclinical experiment for the efficacy 
of a drug. Thus, we selected pamidronate, which is one of 
the most commonly used bisphosphonates for intravenous 
infusion, for administration into the epidural space in rats. 
We  then  performed  behavioral  observations  and  histo-
pathologic analysis to assess neurotoxicity.
MATERIALS  AND  METHODS
1. Study subjects
    F ollowing approval of the Institutional Review Board of 
A n i m a l  E x p e r i m e n t s ,  m a l e  S p r a g u e - D a w l e y  ( S D )  r a t s  
weighing approximately 250-350 g were divided into group 
A (alcohol injection group), group P (pamidronate injection 
group) and group N (normal saline injection group). Each 
group was comprised of 9 rats, and a total of 27 rats were 
examined in the current study. All rats were bred following 
a 1-week adaptation period, with a 12-hr photo cycle. All 
rats showing abnormalities during behavioral observation 
were excluded from the current analysis.
2. Placement of a catheter in the epidural space
    SD rats were anesthetized with inhaled oxygen (3 
L/min) and 4% sevoflurane. Approximately 3 minutes later, 
2 - 3 %  s e v o f l u r a n e  w a s  a d m i n i s t e r e d  w i t h  a  m a s k ,  a n d  
thereby anesthesia was maintained. An epidural catheter 
was prepared by making a knot at 2.5 cm from the tip 
of a 17 cm micro-plastic catheter (PE-10; Natsume Co, 
Japan). An epidural puncture was then performed. That is, 
skin was incised at a length of 2-3 cm and the area ad-
jacent to the supraspinous ligament was dissected. Between 
the 13th thoracic spine and the first lumbar spine, the lig-
amentum flava was exposed with no damage. Using mi-
crosurgical scissors, a small hole was made in the liga-
m e n t u m  f l a v a .  A  c a t h e t e r  w a s  t h e n  i n s e r t e d  a n d  p r o-
gressed toward the tail at a distance of approximately 2.5 
cm, toward the tip of a catheter placed between the 4/5 
lumbar spine. Animals were excluded from the current ex-
periment  if  blood  or  CSF  was  aspirated  through  the 
catheter.  The  remaining  part  of  the  catheter  passed 
through the dermal layer and was then extracted in the 
junction between the cervical and thoracic spine. All scars 
were rinsed with saline. A catheter was passed through 
the center of a knot using a 4-0 silk suture, and tightly 
fixed to the adjacent tissues. Using 1-2 drops of surgical 
glue (alpha cyanoacrylate; Aron-Alpha, Toagosei, Japan), 
the puncture site was sealed. Through a catheter, 2% lido-
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showed normal movement, but posterior legs did not move 
temporarily. If rats died of respiratory distress when given 
lidocaine, it was considered subarachnoid or intravascular 
injection. Following recovery from anesthesia, ambulatory 
posture and vertebral anomaly were examined. Rats show-
ing signs of motor nerve damage, were excluded from the 
current experiment. Each rat was then isolated and raised 
in stabilized conditions [11,12].
3. Drug infusion to the epidural space
    Three days f ollowing insertion of the catheter into the 
epidural space, ambulatory posture, vertebral deformity, 
and abnormal behavior were examined. Further laboratory 
procedures progressed in rats with no abnormal findings. 
Under general anesthesia, animals in group P were injected 
with  pamidronate  (Panorin
Ⓡ,  pamidronate  disodium  15 
mg/1 ml Ampule, Hanlim, Seoul, Korea) 3.75 mg, dissolved 
in saline. In group A, 40% alcohol was injected, and in 
group N, saline was gradually injected at a dose of 0.3 ml 
f or ap pr oxim ate l y 1 m in u te, ex cep t f or the v o lume of a 
catheter. All drugs were newly prepared prior to injection 
a n d  m a n a g e d  u s i n g  a n  a s e p t i c  m e t h o d .  U p o n  r e c o v e r y 
from anesthesia, rats were isolated to be safely bred at 
a 12-hr interval during day and night.
4. Assessment of sensory and motor nerve disturbance 
through behavioral observation
    Acute and chronic toxicity were assessed 2, 7, and 21 
days after injection. Rats were evaluated for sensory and 
motor  nerve  disturbance  and  abnormal  behavior  at  the 
same time each day by 1 investigator blinded to the ex-
perimental procedure.
1) Pinch-toe test: A hind paw was pinched using a forceps 
(01-1155, So l co, Seou l, Kor ea). Then, using a pin c h toe 
test,  motor  and  sensory  nerve  damage  was  assessed 
[13-15]. When the hind paw was pinched by a forceps to 
such an extent that resistance of bone could be perceived 
(deep pinch), observed normal avoidance responses were 
as follows:
  (1) Avoidance of lower extremities
  (2) Crying
  (3) Attempt by the animal to bite the forceps
    In the lower limbs on both sides, if all 3 of the above 
categories were observed at a minimum 5-minute interval 
up to 3 times during a maximum of 6 seconds (cut off 
time), the case was determined to be normal. Otherwise, 
corresponding cases were determined to have an abnormal 
response that indicated the possibility of motor and sen-
sory nerve damage [13].
2) An assessment based on ambulatory pattern and lower 
limb deformity: To examine motor nerve disorders, with the 
application of motor function based on ambulatory pattern 
and the deformity of lower extremities [16], all rats were 
divided into the following grades. Grade 1 = normal gait 
with no evidence of motor paresis; Grade 2 = normal gait 
with  slight  hindpaw  deformity,  plantar  flexion  of  toes; 
Grade  3 = slight gait  disturbance with  motor weakness 
a n d / o r  a n  i n v e r t e d  h i n d p a w ;  a n d  G r a d e  4  =  p r o m i n e n t 
limping gait with dropped hindpaw. Rats corresponding to ＞ 
Grade 2 were all considered to have motor nerve injury.
5. Histopathologic examination
    Tissue samples were collected from the spinal cord on 
day 2 (3 rats/group) for assessment of acute toxicity, and 
on day 7 (3 rats/group) and 21 (3 rats/group) for chronic 
toxicity. Tissue preparation was performed using the same 
method, for which 4% paraformaldehyde in 0.1 M phos-
phate buffer was injected into the heart. Euthanasia was 
thus induced and the cadaver was fixated. In the center 
of the area where the tip of a catheter was placed, ap-
proximately 3 segments of the spinal cord, both superiorly 
and  inferiorly,  including  the  nerve  root,  were  removed. 
Tissue samples were fixated in a 10% formalin solution for 
3 days and then decalcified using 10% formic acid for 2 
weeks. Tissue specimens were rinsed with a buffer solution 
( p H  7 . 4 )  a n d  t h e n  f i x a t e d  u s i n g  2 %  o s m i u m  t e t r o x i d e ,  
which was dissolved in a buffer solution for 30 minutes. 
Dehydration was performed using a graded ethanol, fol-
lowed by an embedding of the tissue sample using epoxy 
resin (agar 100) between teflon-sprayed slides and thick 
acetate foil with a thickness of 100 μm. Tissue samples 
containing the ventral and dorsal horns of the spinal cord 
were dissected and then re-embedded for fine sectioning. 
Tissue samples were then stained using hematoxylin-eosin 
and Luxol fast blue dyes for light microscopy.
    Histopathological findings for assessment of neuro-
toxicity include chromatolysis in the motor neurons of the 
ventral horn of the spinal cord, neuritis, meningeal inflam-
mation, adhesion in periosteum, dura mater, and medulla, 
enlargement of dura mater, peripheral neuropathy, myelin 
loss, and local infarction. To rule out bias, histopathologic 
change was analyzed by 1 pathologist blinded to the study.PB Lee, et al / The Neurotoxicity of Epidural Pamidronate 119
Table 2. Neuropathologic Findings of Spinal Cordand Nerve Under Light Microscopic Examination Following Epidural Drug Injection
Group N Group P Group A
2
nd (n = 3) 7
th (n = 3) 21
st (n = 3) 2
nd (n = 3) 7
th (n = 3) 21
st (n = 3) 2
nd (n = 3) 7
th (n = 3) 21
st (n = 3)
Chromatolysis
Local neuritis
Dural hypertrophy
Synechia
Periopheral neuropathy
Myelin loss
Meningeal inflammation
Local infarction
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
1
-
-
1
0
-
-
-
 3*
1
-
 3*
 3*
1
-
-
2
2
-
2
 3*
2
-
Values are expressed as number of positive animals. Group P: 0.3 ml (3.75 mg) of epidural pamidronate and Groups A and N: the same
volume of epidural alcohol and normal saline, respectively. The  2
nd, 7
th, and 21
st: days after epidural injection of test drugs. *P ＜ 0.05
versus corresponding data of Groups N and P.
Table 1. Evaluation of Pinch-Toe Test and Motor Deficit Following 
Epidural Drug Injection
Days after injection Group N Group P Group A
Pinch-toe test
  2
nd day (n = 9)
  7
th day (n = 6)
  21
st day (n = 3)
Motor deficit
†
  2
nd day (n = 9)
  7
th day (n = 6) 
  21
st day (n = 3)
-
-
-
-
-
-
1 (11)
-
-
1 (11)
-
-
9 (100)*
6 (100)*
3 (100)*
9 (100)*
6 (100)*
3 (100)*
Values are expressed as number (%) of abnormal rats. *P ＜ 0.05
versus corresponding data of Groups N and P. 
†Group P: 0.3 ml 
(3.75 mg) of epidural pamidronate and Groups A and N: the same
volume of epidural alcohol and normal saline, respectively. Grade 
1: normal gait with no evidence of motor paresis, Grade 2: normal
gait with slight hind paw deformity, such as plantar flexion of toes,
Grade 3: slight gait disturbance with motor weakness and/or an 
inverted hindpaw, Grade 4: prominent limping gait with a dropped
hindpaw. Rats with a motor disturbance of grade 2 or above were
considered to have a motor deficit. 
6. Statistical analysis
    Assessment of motor and sensory nerve disorders and 
histopathologic examination of the spinal cord were per-
formed and their results were tested using the Chi-square 
test between the 3 groups. Any cases with a significant 
difference were analyzed using Fisher's exact test between 
the 2 groups, which was followed by Bonferroni correction 
(SigmaStat ver. 2.0, Jandel corporation). A value of P ＜ 
0.05 was considered statistically significant.
RESULTS
    In the P group, with the ex ception of 1 rat, and in the 
N group, no rats showed motor or sensory change, or any 
behavioral change such as aggressive behavior or crying. 
Normal reactions to the pinch-toe test included avoidance, 
crying, and attempts to bite the forceps. All rats in group 
N and all rats, except 1, in group P had a normal gait at 
the time point for all examinations (T able 1). During the 
overall period, however, most rats in Group A showed de-
c r e a s e d  a c t i v i t y  a n d  a p p e t i t e .  I n  g r o u p  A ,  a l l  r a t s  r e-
sponded with some of the 3 aforementioned reactions, or 
had no reaction to the pinch-toe test, and had a gait dis-
turbance of Grade 3 or more (P ＜ 0.05, Table 1). 
    No significantly abnormal histopathologic findings were 
observed in the P and N groups. However, in group A, var-
ious histopathological forms of neurological deficit, such as 
local neuritis, myelin loss, and meningeal inflammation oc-
c u rr ed  a t  e a c h t i m e p o in t  o f  d r u g a d m in is t r a t i o n (P ＜ 
0.05, Table 2, Fig. 1, 2). 
DISCUSSION
    Bisphosphonates show specific, pow erful binding to the 
inorganic matrix of bone, and thereby suppress the matu-
ration and activity of osteoclasts, ultimately causing apop-
tosis of osteoclasts [17,18]. One of the bisphosphonates, 
pamidronate, strongly inhibits bone resorption [1,2]. It is 
a drug that treats hypercalcemia, osteolytic bone meta-
stasis, and Paget's disease due to malignant tumors by in-120 Korean J Pain Vol. 23, No. 2, 2010
Fig. 1. Microscopic findings in spinal cord and nerve on the 2
nd day (A, D, and G), 7
th day (B, E, and H), and 21
st days
(C, F, and I) following epidural injection of alcohol (A-C), pamidronate (D-F), and normal saline (G-I). Hematoxylin and eosin
stain. Figures in middle and right columns (×200) show the high power view of the adjacent left side column (×40) (A, 
D, and G). In the epidural alcohol group, marked vaculolar change of posterior funicules (B) and lymphocytic infiltration
in the spinal cord (C) are visible. In the epidurally-injected pamidronate and normal saline groups, no vacuolation or 
inflammation are visible.
hibiting bone resorption by osteoclasts. 
    Pamidronate has been reported to have ex cellent effi-
cacy in the treatment of chronic lower back pain due to 
osteoporotic fracture, alleviating pain due to bone meta-
s t a s i s  o f  b r e a s t  c a n c e r ,  l o w e r i n g  s e v e r e  b o n e  p a i n  i n  
Paget's disease, improving the pain of cancer metastasis, 
and controlling the pain in complex regional pain syndrome  
[1,19-22].
    Bonabello et al. [3] reported that the antinociceptive 
effects of bisphosphonates occurred with no respect to pe-
ripheral opioid receptors in both the central and peripheral 
nervous systems, with no association in bone lesions. It 
has also been reported that bisphosphonates modify such 
substances  as  prostaglandin  E2,  sensitizing  anti  -  in-
erleukine (IL)-1, anti - IL - 6, and anti-tumor necrosis 
factor - alpha (TNF - alpha) effects, as well as the trau-
matic pain receptor, and thereby have an analgesic effect, 
in addition to inhibiting osteolclastic activity [23]. Another 
study reported that the afferent nerve terminal suppresses 
the release of various neuropeptides following the onset of 
trauma in patients with complex regional pain syndrome  
[22]. In addition, such effects as inhibition of protein pre-
nylation, inhibition of neoangiogenesis, and immune mod-
ulation have an influence on the alleviation of pain [24].PB Lee, et al / The Neurotoxicity of Epidural Pamidronate 121
Fig. 2. Microscopic findings 
in spinal cord and nerve 
following epidural injection 
of alcohol (A, B), pami-
dronate (C, D), and normal 
saline (E, F). Luxol fast blue
stain. Right-side figures 
(×200) (B, D, and F) show 
the high power view of the 
adjacent left side column 
(×40) (A, C, and E). In the 
epidural alcohol group, pale 
and diminished myelin is visi-
ble, and presented as a purple
color (B). In the epidurally- 
injected pamidronate or nor-
mal saline groups, no defi-
nite abnormal morphologic 
findings of myelin are visible.
    Currently, pamidronate is administered via oral route 
or in t r a v en ous in fusion. I t can be a dm in is ter ed u p to a 
maximal dose of 300 mg/d for oral administration and 90 
mg/d for intravenous infusion [24]. However, there are a 
few limitations to administration via the oral route, and 
disadvantages to the oral administration of bisphosphonate 
a r e  a s  f o l l o w s :  1 )  a  l o w e r  r a t e  o f  i n t e s t i n a l  a b s o r p t i o n 
(1-10%) [25]; 2) affection by food ingestion; 3) obligation 
to administer it during the fasting state; and 4) gastro-
intestinal disturbances, such as nausea or abdominal pain. 
Due to these disadvantages, patient compliance has been 
r e p o r t e d  t o  b e  l o w e r  [ 2 5 ] ,  a n d  i n j e c t i o n  m e t h o d s  a r e  
f a v o r e d .  I n t r a v e n o u s  i n j e c t i o n  h a s  m a n y  a d v a n t a g e s  i n  
terms  of  cost-effectiveness  and  patient  compliance.  A 
p e r s i s t e n t  i n t r a v e n o u s  i n f u s i o n  c o n v e r s e l y  i n d u c e s  o s -
teochondrosis, and also produces such adverse effects as 
p h l e b i t i s ,  f e b r i l e  s e n s a t i o n ,  c h i l l i n g  s e n s a t i o n ,  m y a l g i a ,  
malaise, thrombophlebitis, and hypophosphatemia [24,25]. 
In the early stage of administration, adverse effects, such 
as increased bone pain, transient leukocytopenia [26], and 
necrosis of the jaw bone [27,28], used to evolve. In addi-
tion, drugs are expensive and hospitalization is needed for 
an intravenous infusion, which can also be problematic.
    From these findings, we considered the epidural treat-
ment of bisphosphonate as an alternative for non-bone- 
related pain. An epidural approach is currently used most 
prevalently to control pain, and it is more effective than 
other administration routes in cases in which the spinal 
cord is the target of drug administration [29]. Even a mini-
mal dose can produce the same effect, and it is considered 122 Korean J Pain Vol. 23, No. 2, 2010
that systemic adverse effects and risk of neurotoxicity can 
be reduced. It is also advantageous in that inhibition of the 
necessary spinal level can be selective. Pamidronate is also 
expected to have an excellent effectiveness when directly 
administered  to  the  area  adjacent  to  the  spinal  cord. 
However, administration of any drug into the spinal cord 
or an epidural space should be evaluated for potential oc-
c u r r e n c e  o f  n e u r o t o x i c i t y  i n  t h e  s p i n a l  c o r d  [ 1 0 , 2 9 ] .  
Although the addictives that can cause neurotoxicity with 
h i g h e r  p r o b a b i l i t y ,  s u c h  a s  a n t i - o x i d a n t s ,  a n t i - d i s -
infectants, or excipients, could be ruled out, direct admin-
istration of drugs to the area adjacent to the spinal cord 
can cause direct contact between a high-dose of drugs to 
the nerve when compared with other administration routes. 
Therefore, neurological safety must first be demonstrated. 
    The usual dose of pamidronate recommended for pain 
control is 15-60 mg/d in humans. In the current study, the 
dose was 50 times higher than the usual dose for an intra-
venous infusion based on the weight of the rats, which 
corresponds to 750 mg in humans. Because 1/30 of the 
dose for oral administration  is administered via epidural 
route, it is assumed that 22,500 mg is sufficient for a tox-
icity  trial  if  it  is  converted  to  the  dosage  for  oral 
administration. 
    Determination of drug volume has been known to cor-
respond with an epidural infusion of 10-15 ml in humans 
and 0.1 ml in SD rats. In SD rats weighing 250-350 g, 
a contrast medium of 0.3 ml in volume is distributed across 
10-11 segments of the spinal cord. It can therefore be pre-
dicted that most drugs with a viscosity lower than that of 
t h e  c o n t r a s t  m e d i u m  w o u l d  b e  d i s t r i b u t e d  i n  m o r e  e x-
tensive areas. It can therefore be inferred that the dosage 
is sufficient for examination of sensory and motor change 
in the lower limbs, including the 3-6th lumbar nerve root 
[30].
    Although statistically significant neurotoxicity findings 
or ambulatory disorder were not observed on light micro-
scopy, an ambulatory disorder was observed in a rat in the 
P group on day 2 (Grade 4). Because no special abnormal 
findings were observed on light microscopy, it can there-
f ore be inf erred that physical injury caused by catheter 
use, migration of the catheter into the subarachnoid space, 
or intravascular migration of the catheter would be a factor 
responsible for the presence of abnormal findings, rather 
than drug-induced basic changes in nerves.
    In conclusion, epidural administration of pamidronate 
12.5 mg/kg did not produce significant neurotoxic adverse 
effects on behavioral observation and histopathologic ex-
amination in SD rats. Further studies in other animal spe-
cies are warranted to examine the clinical effects of an 
epidural infusion of pamidronate that could lead to clinical 
application. 
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